The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis

Hemophilia A, the most common hereditary disorder, is caused by clotting factor deficiency. Challenges encountered in the current treatment of hemophilia A [factor VIII (FVIII) replacement therapy] due to inhibitor development have caused ineffective treatment as well as morbidity and mortality amon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohar, Kelvin, Prayogo, Stephanie A, Wiyono, Lowilius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288272/
https://www.ncbi.nlm.nih.gov/pubmed/35859961
http://dx.doi.org/10.7759/cureus.26015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288272/
https://www.ncbi.nlm.nih.gov/pubmed/35859961
http://dx.doi.org/10.7759/cureus.26015

Ejemplares similares